Raredr

Phase 2 Glioblastoma Multiforme Trial Underway

Andrew Black
Published Online: Monday, Feb 13, 2017
DelMar Pharmaceuticals has begun dosing patients in their Phase 2 clinical trial of VAL-083 (dianhydrogalactitol) for the treatment of MGMT-unmethylated recurrent Glioblastoma Multiforme (GBM).
 
The study is a Phase 2 single arm clinical trial assessing dianhydrogalactitol in patients 18-years and older diagnosed with MGMT unmethylated, Bevacizumab-naive recurrent GBM. Patients will receive 40 mg/m2 of dianhydrogalactitol through IV for 30-60 minutes on days 1, 2, and 3 of a 21-day treatment-cycle, for up to 12, 21-day treatment cycles.
 
VAL-083 (dianhydrogalactitol) is a small-molecule chemotherapeutic. The drug is deisnged to cross the blood-brain barrier and accumulate in brain tumor tissue. Dianhydrogalactitol’s mechanism of action is bifunctional DNA alkylation at the N7 position of guanine.
 
The clinical trial is currently enrolling patients, to learn more visit https://clinicaltrials.gov/ct2/show/NCT02717962

About Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is a rare but very aggressive form of brain cancer. Glioblastomas can be classified as primary or secondary. Primary glioblastoma tends to occur in older adults (> 50 years) and appear quite suddenly (less than 3 months from initial symptoms to diagnosis). Secondary glioblastoma is less common and occurs in younger patients (< 45 y). These tumors can be present for years before symptoms appear.
 
Standard therapy for glioblastoma consists of surgical resection, radiation therapy, and chemotherapy. Patients treated with this standard therapy tend to survive for approximately 12 months. Without treatment, survival is about 3 months.


Latest Articles
eSight eyewear is the Star Trek like device that allows legally blind 13-year-old, Ethan LaCroix, the ability to play basketball with the Harlem Globetrotters
The 2017 Neuro Film Festival awarded William T. Doorley with the Neuroscience Is…™ Essential award for “Work in Progress: The Remarkable Journey of Dr. Warden.”
Brineura (cerliponase alfa) is an enzyme replacement therapy that in just a few short years has shown itself to be an effective treatment for children with CLN2 disease.
The 2017 Neuro Film Festival recently awarded Meghan Tucker with the Neuroscience Is…™ Critical award for her video, “BethAnn Telford World Marathon Challenge.”
$vacMongoViewPlus$ $vAR$